Literature DB >> 10393052

VEGF increases retinal vascular ICAM-1 expression in vivo.

M Lu1, V L Perez, N Ma, K Miyamoto, H B Peng, J K Liao, A P Adamis.   

Abstract

PURPOSE: Intraocular injections of vascular endothelial growth factor (VEGF), a peptide implicated in the pathogenesis of diabetic retinopathy, can induce retinal ischemia. Diabetic retinal ischemia may be caused, in part, by the adhesion of leukocytes to the retinal vasculature. In this study, the ability of VEGF to increase the expression of intercellular adhesion molecule-1 (ICAM-1) and other adhesion molecules in capillary endothelium and the retinal vasculature was examined.
METHODS: The expression of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin on human brain capillary endothelial cell monolayers exposed to VEGF was quantitated by immunoassay. The effect of VEGF on retinal vascular ICAM-1 expression was determined in ICAM-1 immunofluorescence studies of retinal flat-mounts and in RNase protection assays.
RESULTS: VEGF increased capillary endothelial cell ICAM-1 levels in a dose- and time-dependent manner (6-24 hours, plateau after 6 hours; EC50, 25 ng/ml). VEGF failed to alter E-selectin, P-selectin, or VCAM-1 levels under the conditions tested. Intravitreal injections of pathophysiologically relevant concentrations of VEGF increased ICAM-1 protein and mRNA levels in the retinal vasculature.
CONCLUSIONS: VEGF increases retinal vascular ICAM-1 expression. VEGF-induced increases in ICAM-1 may promote retinal leukostasis in diabetic eyes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393052

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  74 in total

Review 1.  The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Is diabetic retinopathy an inflammatory disease?

Authors:  A P Adamis
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

3.  Pharmacokinetics and safety of intravitreally delivered etanercept.

Authors:  Sascha Fauser; Hubert Kalbacher; Nils Alteheld; Kan Koizumi; Tim U Krohne; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-17       Impact factor: 3.117

4.  Characterization of a mouse model of hyperglycemia and retinal neovascularization.

Authors:  Elizabeth P Rakoczy; Ireni S Ali Rahman; Nicolette Binz; Cai-Rui Li; Nermina N Vagaja; Marisa de Pinho; Chooi-May Lai
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

5.  Generation of transgenic mice with mild and severe retinal neovascularisation.

Authors:  C-M Lai; S A Dunlop; L A May; M Gorbatov; M Brankov; W-Y Shen; N Binz; Y Ky Lai; C E Graham; C J Barry; I J Constable; L D Beazley; E P Rakoczy
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 6.  The pathologic continuum of diabetic vascular disease.

Authors:  Gabriela Orasanu; Jorge Plutzky
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

Review 7.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

8.  Macular microcirculation before and after vitrectomy for macular edema with branch retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Kumi Sakata; Tatsuya Mimura; Sadao Hori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-03       Impact factor: 3.117

9.  Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.

Authors:  Juanjuan Wang; Xueliang Xu; Michael H Elliott; Meili Zhu; Yun-Zheng Le
Journal:  Diabetes       Date:  2010-06-08       Impact factor: 9.461

10.  Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy.

Authors:  Masato Matsuoka; Nahoko Ogata; Keizo Minamino; Miyo Matsumura
Journal:  Mol Vis       Date:  2007-06-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.